ALAMEDA, Calif.--(BUSINESS WIRE)--Mekonos, Inc., a biotech platform company building the future of cell engineering on a chip, today announced it has entered into a partnership agreement with Accelerated Biosciences Corp. (“Accelerated Bio”) to codevelop a powerful, new manufacturing cell line based on Accelerated Bio’s human Trophoblast Stem Cells (hTSCs) and Gene Engineered Multi-Sites (GEMS) technology..

加利福尼亚州阿拉米达市——（商业新闻短讯）——Mekonos，Inc.，一家在芯片上构建细胞工程未来的生物技术平台公司，今天宣布，它已与Accelerated Biosciences Corp.（“Accelerated Bio”）达成合作协议，共同开发一种基于Accelerated Bio的人类滋养层干细胞（hTSCs）和基因工程多位点（GEMS）技术的强大的新型制造细胞系。。

“We are delighted that Accelerated Bio recognizes the long-term potential of our Mekanofection™ platform to unlock delivery of multiplexed payloads into challenging cell types which are not readily accessible with conventional approaches,” said Anil Narasimha, PhD, co-founder and chief executive officer of Mekonos.

Mekonos联合创始人兼首席执行官Anil Narasimha博士说：“我们很高兴Accelerated Bio认识到我们的Mekanofection™平台的长期潜力，可以将多路复用的有效载荷释放到传统方法不易获得的具有挑战性的细胞类型中。”。

“Our platform brings together semiconductor, microfluidic, and surface chemistry technologies to enable the full potential of gene editing for cell therapies and cell engineering through the precise and gentle delivery of a wide variety of molecular cargo into individual cells. We look forward to working closely with the team at Accelerated Bio to enable the development of a next-generation cell line for biomanufacturing from their unique stem cell source.”.

“我们的平台将半导体、微流体和表面化学技术结合在一起，通过将各种分子货物精确而温和地输送到单个细胞中，充分发挥基因编辑在细胞疗法和细胞工程中的潜力。我们期待着与Accelerated Bio的团队密切合作，以便能够从其独特的干细胞来源开发用于生物制造的下一代细胞系。”。

Accelerated Bio out-licenses its commercial grade hTSC platform for drug discovery, therapy development, biomanufacturing and toxicology. The hTSC platform is the earliest ethically sourced pluripotent stem cells that are naive, powerful, lively and have high plasticity. hTSCs also naturally perform functions of many cell types and are immune privileged.

Accelerated Bio out为其用于药物发现、治疗开发、生物制造和毒理学的商业级hTSC平台提供许可。hTSC平台是最早的道德来源的多能干细胞，其幼稚，强大，活泼且具有高可塑性。HTSC也自然地执行许多细胞类型的功能，并且具有免疫特权。

As such, the hTSC platform is an ideal starting material and significantly increases go-to-market potential for a new generation of precision medicine applications..

因此，hTSC平台是理想的起始材料，并显着增加了新一代精准医学应用的市场潜力。。

“We are excited to collaborate with Mekonos to more efficiently and effectively combine our GEMS technology to create stable genetic integration sites with our hTSCs,” said Yuta Lee, founder and chief executive officer of Accelerated Biosciences Corp. “Until now we have struggled to find a good way to insert the GEMS genetic construct into hTSCs without impacting cell health and viability.

加速生物科学公司（Accelerated Biosciences Corp.）创始人兼首席执行官尤塔·李（Yuta Lee）表示：“我们很高兴与Mekonos合作，更有效地结合我们的GEMS技术，与我们的HTSC创建稳定的基因整合位点。到目前为止，我们一直在努力寻找一种好方法，将GEMS基因构建体插入HTSC而不影响细胞健康和活力。

Now, using Mekonos’ delivery platform, which is very gentle on cells, we will be able to develop a cell line which will offer superior manufacturing scale-up and robust growth compared to existing cell lines.”.

现在，使用Mekonos对细胞非常温和的交付平台，我们将能够开发一种细胞系，与现有细胞系相比，该细胞系将提供优越的制造规模和强劲的增长。”。

Cell engineering holds the potential to accelerate biopharma innovation across multiple frontiers – biomanufacturing, cell therapies, drug screening, and disease modeling. However, advanced cell line development is constrained in the industry by a lack of efficient and safe payload delivery methods.

细胞工程有可能加速跨越多个前沿的生物制药创新-生物制造，细胞疗法，药物筛选和疾病建模。然而，由于缺乏有效和安全的有效载荷传递方法，先进的细胞系开发在行业中受到限制。

Both viral vectors and electroporation-based biomolecule delivery have numerous challenges, including cell viability issues, cargo size limitations, cell type restrictions, a lack of dose control, and a lack of precision. These limitations compound and can cause cell functionality compromises and performance issues downstream, given the lack of consistency in engineered cells and inefficient scale-up..

病毒载体和基于电穿孔的生物分子递送都有许多挑战，包括细胞活力问题，货物大小限制，细胞类型限制，缺乏剂量控制和缺乏精确度。鉴于工程细胞缺乏一致性和放大效率低下，这些限制会加剧，并可能导致细胞功能受损和下游性能问题。。

“Resolving these issues with better manufacturing and delivery techniques is a ‘holy grail’ that has remained out of reach for the biotechnology industry – until now. Mekonos recognizes there is a better way, and we are rising to the challenge,” Narasimha added.

纳拉西姆哈补充说：“用更好的制造和交付技术解决这些问题是生物技术行业迄今无法企及的‘圣杯’。Mekonos认识到还有更好的方法，我们正在迎接挑战。”。

About Mekonos, Inc.

关于Mekonos，Inc。

Mekonos is using its proprietary cell-engineering platform to create a future where personalized medicine is accessible to all. By uniting three core technologies to teach individual cells how to fight disease, Mekonos’ platform is overcoming present day obstacles by enabling unprecedented precision in the delivery of multiplexed cargo into even the most fragile of cells..

Mekonos正在利用其专有的细胞工程平台创造一个人人都能获得个性化医疗的未来。Mekonos平台将三项核心技术结合起来，教授单个细胞如何对抗疾病，从而克服了当今的障碍，实现了将多路复用货物输送到最脆弱的细胞中的前所未有的精确性。。

This approach offers collaborators a scalable solution to seamlessly move from research and discovery applications all the way through manufacturing and opens the doors to a new world of possibilities, including personalized medicine in a point-of-care setting.

这种方法为合作者提供了一个可扩展的解决方案，可以从研究和发现应用程序无缝地移动到整个制造过程，并为新的可能性世界打开了大门，包括在护理点环境中的个性化医疗。

Mekonos is headquartered in Alameda, CA and backed by leading healthcare and technology investors. For more information, please visit www.mekonos.com and follow us on LinkedIn.

Mekonos总部位于加利福尼亚州阿拉米达，由领先的医疗保健和技术投资者支持。有关更多信息，请访问www.mekonos.com并在LinkedIn上关注我们。

About Accelerated Biosciences Corp.

关于加速生物科学公司。

Accelerated Bio represents a transformative approach in the healthcare sector by leveraging the groundbreaking potential of hTSCs to revolutionize precision medicine. Originating from an ethical source, the hTSCs possess the extraordinary ability to perform functions of many cell types with added genetic stability, natural immune privilege, and high expansion capacity.

加速生物技术通过利用HTSC的开创性潜力彻底改变精准医学，代表了医疗保健领域的一种变革性方法。源自道德来源的hTSC具有执行多种细胞类型功能的非凡能力，具有额外的遗传稳定性，天然免疫特权和高扩展能力。

The hTSCs are setting the stage for groundbreaking precision medicine applications. Accelerated Bio’s large, robust and encumbrance-free intellectual property estate ensures Accelerated Bio’s and its partners’ freedom to innovate..

HTSC正在为开创性的精准医学应用奠定基础。Accelerated Bio拥有庞大、强大且无产权负担的知识产权，确保了Accelerated Bio及其合作伙伴的创新自由。。

Accelerated Bio is headquartered in Philadelphia, PA and is focused on commercializing its hTSC platform with its partners. For more information about Accelerated Biosciences, visit www.acceleratedbio.com and follow us on LinkedIn.

Accelerated Bio总部位于宾夕法尼亚州费城，专注于与合作伙伴将其hTSC平台商业化。有关加速生物科学的更多信息，请访问www.acceleratedbio.com并在LinkedIn上关注我们。